Your browser doesn't support javascript.
loading
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.
Heudel, P; Chabaud, S; Perol, D; Flechon, A; Fayette, J; Combemale, P; Tredan, O; Desseigne, F; de la Fouchardiere, C; Boyle, H; Perol, M; Bachelot, T; Cassier, P; Avrillon, V; Terret, C; Michallet, A-S; Neidhardt-Berard, E-M; Nicolas-Virelizier, E; Dufresne, A; Belhabri, A; Brahmi, M; Lebras, L; Nicolini, F; Sarabi, M; Rey, P; Bonneville-Levard, A; Rochefort, P; Provensal, A-M; Eberst, L; Assaad, S; Swalduz, A; Saintigny, P; Toussaint, P; Guillermin, Y; Castets, M; Coutzac, C; Meeus, P; Dupré, A; Durand, T; Crochet, H; Fervers, B; Gomez, F; Rivoire, M; Gregoire, V; Claude, L; Chassagne-Clement, C; Pilleul, F; Mognetti, T; Russias, B; Soubirou, J-L.
Affiliation
  • Heudel P; Centre Léon Bérard, Lyon, France.
  • Chabaud S; Centre Léon Bérard, Lyon, France.
  • Perol D; Centre Léon Bérard, Lyon, France.
  • Flechon A; Centre Léon Bérard, Lyon, France.
  • Fayette J; Centre Léon Bérard, Lyon, France.
  • Combemale P; Centre Léon Bérard, Lyon, France.
  • Tredan O; Centre Léon Bérard, Lyon, France; Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Desseigne F; Centre Léon Bérard, Lyon, France.
  • de la Fouchardiere C; Centre Léon Bérard, Lyon, France.
  • Boyle H; Centre Léon Bérard, Lyon, France.
  • Perol M; Centre Léon Bérard, Lyon, France.
  • Bachelot T; Centre Léon Bérard, Lyon, France; Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Cassier P; Centre Léon Bérard, Lyon, France.
  • Avrillon V; Centre Léon Bérard, Lyon, France.
  • Terret C; Centre Léon Bérard, Lyon, France.
  • Michallet AS; Centre Léon Bérard, Lyon, France.
  • Neidhardt-Berard EM; Centre Léon Bérard, Lyon, France.
  • Nicolas-Virelizier E; Centre Léon Bérard, Lyon, France.
  • Dufresne A; Centre Léon Bérard, Lyon, France; Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Belhabri A; Centre Léon Bérard, Lyon, France.
  • Brahmi M; Centre Léon Bérard, Lyon, France; Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Lebras L; Centre Léon Bérard, Lyon, France.
  • Nicolini F; Centre Léon Bérard, Lyon, France; Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Sarabi M; Centre Léon Bérard, Lyon, France; Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Rey P; Centre Léon Bérard, Lyon, France.
  • Bonneville-Levard A; Centre Léon Bérard, Lyon, France.
  • Rochefort P; Centre Léon Bérard, Lyon, France.
  • Provensal AM; Centre Léon Bérard, Lyon, France.
  • Eberst L; Centre Léon Bérard, Lyon, France.
  • Assaad S; Centre Léon Bérard, Lyon, France.
  • Swalduz A; Centre Léon Bérard, Lyon, France.
  • Saintigny P; Centre Léon Bérard, Lyon, France; Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Toussaint P; Centre Léon Bérard, Lyon, France.
  • Guillermin Y; Centre Léon Bérard, Lyon, France.
  • Castets M; Centre Léon Bérard, Lyon, France; Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Coutzac C; Centre Léon Bérard, Lyon, France; Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Meeus P; Centre Léon Bérard, Lyon, France.
  • Dupré A; Centre Léon Bérard, Lyon, France.
  • Durand T; Centre Léon Bérard, Lyon, France.
  • Crochet H; Centre Léon Bérard, Lyon, France.
  • Fervers B; Centre Léon Bérard, Lyon, France.
  • Gomez F; Centre Léon Bérard, Lyon, France.
  • Rivoire M; Centre Léon Bérard, Lyon, France; Centre Léon Bérard & Université Claude Bernard, Lyon, France.
  • Gregoire V; Centre Léon Bérard, Lyon, France.
  • Claude L; Centre Léon Bérard, Lyon, France.
  • Chassagne-Clement C; Centre Léon Bérard, Lyon, France.
  • Pilleul F; Centre Léon Bérard, Lyon, France; Centre Léon Bérard & Université Claude Bernard, Lyon, France.
  • Mognetti T; Centre Léon Bérard, Lyon, France.
  • Russias B; Centre Léon Bérard, Lyon, France.
  • Soubirou JL; Centre Léon Bérard, Lyon, France.
ESMO Open ; 6(1): 100044, 2021 02.
Article in En | MEDLINE | ID: mdl-33516148
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Second Primary / Immune Checkpoint Inhibitors Type of study: Guideline / Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: ESMO Open Year: 2021 Type: Article Affiliation country: France
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Second Primary / Immune Checkpoint Inhibitors Type of study: Guideline / Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: ESMO Open Year: 2021 Type: Article Affiliation country: France